Here are the 10-K annual reports from Vivos Inc (RDGL) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow RDGL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RDGL filings page.
Vivos Inc. (RDGL) is a development‑stage radiation oncology device company focused on its Y‑90–based RadioGel® for humans and IsoPet® for animals. It reported strong operational traction in veterinary oncology, including a 1,200% year‑over‑year increase in IsoPet® therapies from 2024 to 2025, more than 100 treatments with zero reportable serious adverse events, and 17 certified clinics across the U.S. as of December 31, 2025.
To support growth and regulatory progress, Vivos is building a multi‑site manufacturing network, adding a domestic facility at the Applied Process Engineering Laboratory in Washington and pursuing an international site in India through its new subsidiary Vivos Scientific India LLP, which also advances human and animal trials there. The company strengthened its intellectual property with new patents and trademarks, including U.S. Patent No. 12,521,452 B2 protecting its hydrogel‑based Precision Radionuclide Therapy™ platform, and continues preparing an FDA Investigational Device Exemption resubmission for RadioGel® with guidance from a specialized regulatory expert.
Financially, Vivos remains highly dependent on external capital. It had $1,558,525 in cash at December 31, 2025, an accumulated deficit of $88,427,246, and net losses of $3,066,017 in 2025, and its auditors expressed substantial doubt about its ability to continue as a going concern. The company estimates it needs about $3.0 million per year, or $9.0 million over 36 months, to fund operations, FDA processes, initial clinical trials, clinic activation, and manufacturing build‑out, and is relying heavily on successive Regulation A+ equity offerings and potential partnerships to proceed.